SenzaGen AB (STO:SENZA)

Market Cap	141.32M
Revenue (ttm)	57.02M
Net Income (ttm)	-18.89M
Shares Out	29.50M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,723
Average Volume	23,936
Open	4.900
Previous Close	4.780
Day's Range	4.750 - 4.900
52-Week Range	3.860 - 9.680
Beta	0.30
RSI	41.01
Earnings Date	May 14, 2025

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; GARD air: respiratory sensitization assessment, and the GARD® technology. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, skin sensitization medical device services; tailored advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services inclu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2024, SenzaGen AB's revenue was 57.70 million, an increase of 15.69% compared to the previous year's 49.87 million. Losses were -17.85 million, -19.22% less than in 2023.